Heart Failure Society of America Annual Scientific Meeting 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Heart Failure and Transplant Cardiologists, General Cardiologists, Interventional Cardiologists, Cardiac Electrophysiologists

+ Sample video: contact me for sample video

+ Information:

• Conference Title: Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

• Organizer: Heart Failure Society of America (HFSA)

• Description: The Heart Failure Society of America (HFSA) Annual Scientific Meeting is the premier conference for healthcare professionals dedicated to the research, prevention, diagnosis, and treatment of heart failure. Bringing together renowned cardiovascular experts, researchers, and multidisciplinary clinicians, the program delivers state-of-the-art updates across the entire spectrum of heart failure care. Through plenary sessions, late-breaking clinical trials, interactive debates, case-based workshops, and scientific abstracts, the meeting covers guideline-directed medical therapy (GDMT), acute decompensated heart failure, cardiogenic shock, mechanical circulatory support (MCS), heart transplantation, inherited and infiltrative cardiomyopathies, cardiorenal-metabolic syndromes, device therapies, and multidisciplinary care delivery models.

Learning Objectives

Upon completion of this educational activity, participants should be better able to:

• Implement current Guideline-Directed Medical Therapy (GDMT) and emerging pharmacologic strategies for patients with Heart Failure with Reduced Ejection Fraction (HFrEF), Mildly Reduced Ejection Fraction (HFmrEF), and Preserved Ejection Fraction (HFpEF).

• Evaluate and manage acute decompensated heart failure (ADHF) and cardiogenic shock using contemporary hemodynamic monitoring and temporary mechanical circulatory support (tMCS).

• Apply best practices in candidate selection, perioperative care, and long-term management of durable Left Ventricular Assist Devices (LVADs) and cardiac transplantation.

• Diagnose and treat specific cardiomyopathy phenotypes, including cardiac amyloidosis, hypertrophic cardiomyopathy (HCM), cardiac sarcoidosis, myocarditis, and genetic cardiomyopathies.

• Integrate novel therapies addressing the cardiorenal-metabolic continuum, including SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists.

• Determine appropriate indications for electrophysiologic interventions, including catheter ablation, cardiac resynchronization therapy (CRT), conduction system pacing, and implantable cardioverter-defibrillators (ICDs).

• Optimize multidisciplinary team-based care, remote patient monitoring, health equity initiatives, and palliative care integration to reduce hospital readmissions and improve patient quality of life.

Target Audience

The HFSA Annual Scientific Meeting is designed for physicians, cardiologists, heart failure specialists, cardiovascular surgeons, internists, pharmacists, nurse practitioners, physician assistants, registered nurses, researchers, and other healthcare professionals involved in the care of patients with heart failure and cardiomyopathy.

Best for Heart Failure and Transplant Cardiologists, General Cardiologists, Interventional Cardiologists, Cardiac Electrophysiologists, Cardiothoracic Surgeons, Critical Care Physicians, Internists, Nephrologists, Endocrinologists, Pulmonologists, Medical Geneticists, and Palliative Care Specialists.

Topics

Track 1: Chronic Heart Failure & Guideline-Directed Medical Therapy (GDMT)

• Rapid Sequencing and Optimization of the Four Pillars of HFrEF Therapy (ARNI, Beta-Blockers, MRA, SGLT2i)

• Diagnostic Algorithms and Phenotype-Specific Management of HFpEF and HFmrEF

• Management of Heart Failure with Improved Ejection Fraction (HFimpEF)

• Overcoming Therapeutic Inertia: Strategies for Titrating GDMT in Outpatient and Inpatient Settings

• Novel Pharmacotherapies in Clinical Trials: Soluble Guanylate Cyclase Stimulators, Cardiac Myosin Activators/Inhibitors, and Anti-Inflammatory Agents

• Managing Worsening Heart Failure (WHF) Events in the Ambulatory Setting

Track 2: Acute Heart Failure, Cardiogenic Shock & Critical Care Cardiology

• Contemporary Classification and Staging of Cardiogenic Shock (SCAI Shock Stages)

• Invasive Hemodynamic Assessment and Pulmonary Artery Catheterization in the Cardiac Intensive Care Unit (CICU)

• Decongestion Strategies in Acute Decompensated Heart Failure: Diuretic Resistance, Sequential Nephron Blockade, and Ultrafiltration

• Temporary Mechanical Circulatory Support (tMCS): Intra-Aortic Balloon Pump (IABP), Impella, TandemHeart, and VA-ECMO

• Shock Team Protocols, Regionalized Networks, and Escalation/De-escalation Algorithms

• Management of Right Ventricular Failure in the Critically Ill Patient

Track 3: Advanced Heart Failure, Durable MCS & Heart Transplantation

• Patient Selection and Timing of Referral for Advanced Heart Failure Therapies

• Durable Left Ventricular Assist Devices (LVAD): Hemocompatibility, Pump Thrombosis, GI Bleeding, and Driveline Infections

• Advances in Heart Transplantation: Donor Pool Expansion, Donation After Circulatory Death (DCD), and Ex Vivo Organ Perfusion

• Contemporary Immunosuppression Regimens and Desensitization Strategies in Sensitized Transplant Candidates

• Non-Invasive Surveillance for Cardiac Allograft Rejection: Donor-Derived Cell-Free DNA (dd-cfDNA) and Gene Expression Profiling

• Prevention, Diagnosis, and Management of Cardiac Allograft Vasculopathy (CAV)

Track 4: Cardiomyopathies, Myocarditis & Genetic Heart Disease

• Transthyretin Cardiac Amyloidosis (ATTR-CM): Non-Invasive Diagnosis, TTR Stabilizers, Silencers, and Emerging Depleters

• Hypertrophic Cardiomyopathy (HCM): Integration of Cardiac Myosin Inhibitors, Septal Reduction Therapy, and Sudden Death Risk Stratification

• Inflammatory Cardiomyopathies: Diagnostic Imaging and Immunosuppression in Cardiac Sarcoidosis and Giant Cell Myocarditis

• Acute and Fulminant Myocarditis: Etiologies, Endomyocardial Biopsy Indications, and Long-Term Sequelae

• Genetic Testing and Cascade Screening in Dilated, Arrhythmogenic, and Non-Compaction Cardiomyopathies

• Peripartum Cardiomyopathy and Cardio-Obstetrics: Risk Stratification and Management Across Pregnancy

• Cardio-Oncology: Prevention, Surveillance, and Management of Cancer Therapy-Related Cardiac Dysfunction (CTRCD)

Track 5: Cardiorenal-Metabolic Syndrome & Comorbidities

• The Cardiorenal-Metabolic Axis: Interplay Between Heart Failure, Chronic Kidney Disease (CKD), Diabetes, and Obesity

• GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Obesity-Related HFpEF

• Managing Hyperkalemia and Worsening Renal Function During RAASi and MRA Therapy

• Diagnosis and Treatment of Iron Deficiency and Anemia in Heart Failure: Intravenous Iron Supplementation

• Sleep-Disordered Breathing (Obstructive and Central Sleep Apnea) in Heart Failure

Track 6: Pulmonary Hypertension & Right Heart Failure

• Differentiating Pulmonary Arterial Hypertension (PAH – Group 1) from Pulmonary Hypertension Due to Left Heart Disease (PH-LHD – Group 2)

• Invasive Hemodynamic Exercise Testing in Unexplained Dyspnea and Combined Pre- and Post-Capillary PH (CpcPH)

• Targeted Pulmonary Vasodilator Therapies and Emerging Activin Signaling Inhibitors

• Comprehensive Evaluation and Management of Isolated Right Ventricular Failure and Tricuspid Regurgitation

Track 7: Electrophysiology, Devices & Structural Heart Interventions in Heart Failure

• Atrial Fibrillation in Heart Failure: Catheter Ablation vs. Medical Therapy and Rate/Rhythm Control

• Ventricular Arrhythmias in Ischemic and Non-Ischemic Cardiomyopathy: ICD Indications and Catheter Ablation

• Advances in Pacing: Cardiac Resynchronization Therapy (CRT), His-Bundle Pacing, and Left Bundle Branch Area Pacing (LBBAP)

• Neuromodulation and Device-Based Therapies: Cardiac Contractility Modulation (CCM) and Baroreflex Activation Therapy (BAT)

• Transcatheter Edge-to-Edge Repair (TEER) and Transcatheter Valve Replacement for Secondary Mitral and Tricuspid Regurgitation

• Implantable Hemodynamic Monitors and Remote Dielectric Sensing for Guiding Heart Failure Therapy

Track 8: Multidisciplinary Care, Digital Health, Health Equity & Palliative Care

• Artificial Intelligence, Machine Learning, and Wearable Technologies in Heart Failure Prediction and Monitoring

• Optimizing Transitions of Care, Post-Discharge Clinics, and Hospital-at-Home Models

• Addressing Social Determinants of Health (SDOH) and Disparities in Heart Failure Outcomes and Transplant Allocation

• Exercise Training, Cardiac Rehabilitation, and Nutritional Interventions in Heart Failure

• Shared Decision-Making, Advance Care Planning, Symptom Management, and Palliative Care in End-Stage Heart Failure